Highly Sensitive Measurement of Glomerular Permeability in Mice with Fluorescein Isothiocyanate-polysucrose 70
August 9th, 2019
6.3K views
Here, we present a protocol to test glomerular permeability in mice using a highly sensitive, nonradioactive tracer. This method allows repetitive urine analyses with small urine volumes.
Overview
This article presents a protocol for testing glomerular permeability in mice using a sensitive, nonradioactive tracer. This method enables repetitive urine analyses with minimal urine volumes.
Key Study Components
Area of Science
- Nephrology
- Kidney disease research
- Glomerular function assessment
Background
- Understanding glomerular permeability is crucial in kidney disease.
- Current methods may not detect small changes in permeability.
- This protocol aims to improve detection sensitivity.
- Fluorescent tracers provide a nonradioactive alternative for studies.
Purpose of Study
- To evaluate glomerular permeability in a mouse model.
- To assess the impact of small increases in permeability on kidney function.
- To provide a reliable method for nephrology research.
Methods Used
- Use of a fluorescent lead labeled tracer for detection.
- Administration of anesthesia to the mice.
- Placement of a urinary catheter in female mice.
- Positioning the mouse in dorsal recumbency for the procedure.
Main Results
- Small and transient increases in glomerular permeability can be detected.
- The method allows for repeated measurements with minimal urine volume.
- Fluorescent tracers enhance the sensitivity of the analysis.
- The protocol is straightforward and reproducible.
Conclusions
- This method provides a valuable tool for nephrology research.
- It enables better understanding of glomerular function in health and disease.
- Future studies can leverage this technique for deeper insights into kidney pathology.
Frequently Asked Questions
What is the main advantage of this method?
The main advantage is the ability to detect small and transient increases in glomerular permeability using a fluorescent tracer.
How is the urinary catheter placed?
The catheter is placed after anesthetizing the mouse and positioning it in dorsal recumbency.
Can this method be used repeatedly?
Yes, the method allows for repetitive urine analyses with small urine volumes.
What type of tracer is used in this protocol?
A fluorescent lead labeled tracer is used for detecting glomerular permeability.
Is this method non-invasive?
While the method involves catheterization, it is designed to minimize discomfort and is considered less invasive than traditional methods.
What are the implications of this research?
This research can help answer key questions about the role of glomerular permeability in kidney disease.
Executive Industry Relevance
This method enables detection of small, transient increases in glomerular permeability using a nonradioactive fluorescent tracer, addressing a critical gap in early kidney disease biomarker discovery. By allowing repetitive urine analysis with minimal sample volume, it supports longitudinal monitoring in preclinical models, improving predictive confidence in target validation and mechanistic de-risking for renal therapeutics.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Interrogates therapeutic hypotheses by quantifying glomerular permselectivity changes in response to pharmacological modulators.
- Operational Value: Enables functional target validation through direct measurement of tracer flux, reducing reliance on indirect albuminuria endpoints.
- Predictive Value: Supports portfolio triage by detecting early permeability shifts that may predict later pathological outcomes.
Screening & Assay Development
- Assay Readiness: Prepares validated biological systems for downstream compound screening by establishing baseline permeability metrics.
- Quantitative Output: Generates fluorescence-based readouts normalized to creatinine, enabling standardized, reproducible measurements across studies.
- Scalability: Facilitates high-frequency sampling with low urine volume requirements, supporting longitudinal assay designs.
Translational & Preclinical Research
- Disease Relevance: Models human glomerular dysfunction by capturing permeability changes induced by angiotensin II, a known pathophysiological mediator.
- Translational Continuity: Bridges discovery and preclinical phases by providing a consistent permeability readout across intervention and washout phases.
- Risk-Adjusted Decisions: Informs go/no-go criteria by demonstrating reversibility of permeability changes with receptor blockade, supporting mechanistic de-risking.
Pipeline & Workflow Integration
The method fits within the discovery-to-preclinical continuum, enabling hypothesis-driven assessment of glomerular function prior to lead optimization and supporting data-driven advancement decisions.
- Discovery Biology: Supports mechanistic interrogation of pathways affecting glomerular barrier integrity, such as RAAS modulation.
- Screening: Delivers assay-ready systems with standardized tracer handling and fluorescence detection protocols.
- Analytics: Provides quantitative, normalized fluorescence intensity measurements that allow comparison of permeability states across experimental conditions.
- Translational Research: Connects early permeability changes to preclinical validation by tracking responses to angiostensin II and its blockade.
- Enterprise Reuse: Establishes a reusable permeability testing platform applicable across multiple renal disease models and therapeutic areas.
Operational & Enterprise Impact
- Scientific Value: Enhances target confidence by detecting subtle, early-stage permeability changes missed by conventional biomarkers.
- Operational Value: Improves reproducibility through standardized catheterization, infusion, and fluorescence measurement procedures.
- Strategic Value: Increases capital efficiency by enabling early detection of ineffective compounds, reducing late-stage failure risk.
- Portfolio Impact: Supports risk-adjusted prioritization by identifying compounds that modulate glomerular permselectivity with mechanistic clarity.
Implementation Considerations
- Requires expertise in murine vascular access and urinary catheterization techniques.
- Dependent on fluorescence plate reader instrumentation capable of excitation/emission at 490/525 nm for FITC detection.
- Necessitates cross-team standardization of urine collection, handling, and creatinine normalization procedures.
- Involves adaptation considerations when translating protocols across strains, sexes, or disease models.
- Limited by the need for careful air embolism prevention during infusion solution changes, as noted in procedural controls.
Biopharma FAQs
Why does null hypothesis testing matter for target validation?
Null hypothesis testing determines whether observed changes in FITC-polysucrose 70 flux exceed background variability, providing statistical confidence that a compound truly alters glomerular permeability rather than producing false-positive signals.
How does independent variable isolation fit the discovery pipeline?
Isolating the independent variable (e.g., angiotensin II concentration) ensures that changes in tracer flux are attributable to the specific modulator being tested, supporting clear mechanism-of-action assignment in early target validation.
What quantitative dependent variable measurements enable?
Measuring fluorescence intensity of FITC-polysucrose 70 normalized to creatinine enables quantitative assessment of glomerular permeability shifts, allowing dose-response modeling and comparison across treatment groups.
Why do replication requirements matter for cross-functional collaboration?
Repeating measurements ten times per time point ensures data reliability, which is essential for aligning discovery biology, pharmacology, and toxicology teams around consistent permeability endpoints.
What statistical analysis capabilities are required before implementation?
Implementation requires the ability to perform group comparisons (e.g., control vs. treated) using appropriate statistical tests to determine significant differences in tracer flux, supporting go/no-go decisions based on permeability outcomes.
Chapters in this video
0:04
Title
0:28
Preparation Phase Urinary Catheter
1:43
Preparation Phase - Central Venous Catheter
4:16
Blood Pressure Measurement and Equilibration Phase
5:51
Experimental Phase
7:10
Results: Fluorescence Scan, Glomerular Permeability and Blood Pressure
9:00
Conclusion
